Es ist nicht klar, wie groß die Rolle von Antibiotika https://antibiotika-wiki.de/ in den Wettbewerbsbeziehungen zwischen Mikroorganismen unter natürlichen Bedingungen ist. Zelman vaxman glaubte, dass diese Rolle minimal ist, Antibiotika werden nicht anders als in reinen Kulturen auf reichen Umgebungen gebildet. Anschließend wurde jedoch festgestellt, dass bei vielen Produzenten die Aktivität der antibiotikasynthese in Gegenwart anderer Arten oder spezifischer Produkte Ihres Stoffwechsels zunimmt.
A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured population
EXHIBIT 102 Clinical Therapeutics/Volume 30, Number 10, 2008 A Retrospective Study of the Use of Fluticasone Propionate/ Salmeterol Combination as Initial Asthma Controller Therapy in a Commercially Insured Population
Howard Friedman, PhD1; Teresa Wilcox, PhD2; Gregory Reardon, PhD3; Simone Crespi, MPH4; and Barbara P. Yawn, MD, MSc5
1Analytic Solutions, Inc., New York, New York; 2United BioSource Corporation, Bethesda, Maryland; 3Informagenics, LLC, Worthington, Ohio; 4Schering-Plough Corporation, Kenilworth, New Jersey; and 5Ol-msted Medical Center, Minneapolis, MinnesotaABSTRACT
had an ED visit with an OCS prescription, and 1.5%
Background: Asthma management guidelines state
that a low-dose inhaled corticosteroid (ICS) is the
Conclusion: More than two thirds of the patients
preferred treatment for mild persistent asthma and
who initiated FPS treatment had neither received an ICS
that coadministration of a long-acting β -agonist
prescription before their first FPS pharmacy claim nor
(LABA) should be reserved for patients whose asthma
had evidence of asthma severity that would appear to
is uncontrolled by single-entity ICS. However, it ap-
warrant the use of an ICS/LABA combination. (Clin Ther.
pears that many patients in the United States with
2008;30:1908–1917) 2008 Excerpta Medica Inc.
mild persistent asthma are initially treated with com-
Key words: asthma guidelines, inhaled cortico-
binations of fluticasone propionate/salmeterol (FPS).
steroids, fluticasone propionate/salmeterol, initial thera-
Objective: The aim of this study was to examine
whether use of FPS was consistent with asthma man-agement guidelines. Methods: A commercial insurance database was INTRODUCTION
analyzed retrospectively to identify patients aged 12 to
Low-dose inhaled corticosteroid (ICS) therapy is rec-
62 years who had ≥1 pharmacy claim for FPS between
ommended by the National Asthma Education and
October 1, 2004, and September 30, 2006. An index
Prevention Program (NAEPP) guidelines as the pre-
date corresponding to the date of the first FPS phar-
ferred initial treatment for patients with mild persis-
macy claim was assigned to each patient. Medi-
tent asthma.1 The NAEPP guidelines also state that a
cal and pharmacy claims data were analyzed for the
long-acting β -agonist (LABA), such as salmeterol or
365-day period before the index date (preindex peri-
formoterol, may be used with an ICS for moderate to
od). The severity of patients’ asthma was inferred from
severe persistent asthma if control is inadequate, as
their history of claims. Patients were identified as hav-
indicated by manifestations such as frequent symp-
ing more severe asthma if, during the preindex peri-
toms or nocturnal awakenings or overreliance on a
od, they either received >365 doses of short-acting
β -agonists (SABAs), an oral corticosteroid (OCS), or an
The recommendations for LABA use promulgated
emergency department (ED) asthma visit with an OCS
by asthma treatment guidelines should be considered in
prescription, or were hospitalized for their asthma.
the context of advisory and boxed warnings issued by
Results: Among 87,459 patients with new FPS
the US Food and Drug Administration (FDA). In No-
claims, 60.8% were female, and the mean age was
vember 2005, the FDA issued a public health advisory
37.3 years. Of these patients, 60,453 (69.1%) had no preindex ICS pharmacy claim or claims that would
Accepted for publication August 14, 2008.
indicate moderate or severe asthma. In the preindex
period, only 6.3% had received an ICS, 7.4% had
>365 SABA doses, 22.7% had used an OCS, 1.1%
2008 Excerpta Medica Inc. All rights reserved. Volume 30 Number 10 H. Friedman et al.
about the increased risk of deaths and life-threatening
Minnesota) was studied to capture data on patients
experiences in asthma patients using LABAs.2 This warn-
who started FPS therapy between October 1, 2004,
ing reflected the findings of the Salmeterol Multicenter
and September 30, 2006 (index date). This database
Asthma Research Trial (SMART), which was conducted
includes patients in exclusive-provider organizations,
between 1996 and 2003.3 The SMART study investi-
health maintenance organizations, indemnity plans,
gated the safety of adding salmeterol or placebo to usual
point-of-service plans, and preferred-provider organi-
asthma care, which included ICS use (47% of the study
zations (specific features of these plans are not noted
population) in patients aged ≥12 years who had not
in the database). It contains data about enrollment,
previously used LABAs. The data revealed a small, but
medical and pharmacy claims, and laboratory tests
significant, increase in respiratory- and asthma-related
for 24 million beneficiaries covered over a period of
deaths when compared with placebo (respiratory-related
4.5 years and 14 million beneficiaries continuously
deaths: 24 vs 11, relative risk, 2.16 [95% CI, 1.06–
enrolled for 12 months. The vast majority of benefi-
4.41]; asthma-related deaths: 13 vs 3, relative risk, 4.37
ciaries are covered by commercial insurance (93%),
[95% CI, 1.25–15.34]). In March 2006, the FDA man-
with Medicaid (5%) and Medicare (2%) covering the
dated boxed warnings for LABAs.4 The current labeling
remainder. Approximately 75% of the beneficiaries are
for ICS/LABA combination products, including flutica-
located in the south or north central United States.
sone propionate/salmeterol (FPS), contains a boxed warn-
An index date corresponding to the date of the first
ing stating that LABAs may increase the risk of asthma-
FPS pharmacy claim during the time period between
related death and that ICS/LABA combinations should
October 1, 2004, and September 30, 2006, was as-
be prescribed only for patients who are not adequately
signed to each identified patient. Medical and
controlled on other asthma-controller medications or
pharmacy claims data were analyzed for the 365-day
whose disease severity clearly warrants initiation of treat-
period before the index date (preindex period).
ment with 2 maintenance therapies.5 Despite the NAEPP
Institutional review board approval was not re-
guidelines and the boxed warning, it has been reported
quired for this retrospective study. The privacy of each
that approximately one third of patients with mild per-
patient was protected by the assignment of a number
sistent asthma are treated with FPS.6 A recent review of
to serve as a unique identifier before any data were
administrative claims data from the Arkansas Medicaid
and State Child Health Insurance Program (SCHIP) found that only 11% of asthma patients who had re-
Study Population
ceived prescriptions for FPS had a previous claim for an
To be eligible for inclusion in the study (Figure 1),
ICS prescription.7 In addition, fewer than 25% of the
patients were required to have at least 1 pharmacy
patients who received FPS prescriptions had used phy-
claim for FPS during the patient identification period,
sician services, rescue medications, or systemic corti-
be aged 12 to 62 years on the index date, be eligible
costeroids at levels suggestive of moderate or severe
for pharmacy and medical benefits, and be continu-
persistent asthma during the 6 to 12 months before
ously enrolled in the health plan for at least 12 months
before the index date. The age range for inclusion was
Using data from a large commercial insurance data-
selected because all ICSs are approved for use in pa-
base, the present study investigated the proportion of
tients aged ≥12 years, and because many patients aged
asthma patients who were newly prescribed FPS with-
>62 years are covered by Medicare rather than com-
out evidence of an initial trial of single-entity ICS or
mercial insurance. In addition, several exclusion crite-
whose resource utilization data did not indicate a dis-
ria were applied: any medical service claim coded
ease severity that warranted the use of an ICS/LABA
during the preindex period (or on the index date) with
fixed combination, to determine whether the use of FPS
a primary or secondary diagnosis of chronic obstruc-
was consistent with asthma management guidelines.
tive pulmonary disease (International Classification of Diseases, Ninth Revision, Clinical ModificationMATERIALS AND METHODS
[ICD-9-CM] codes 491.xx, 492.xx, 493.2x, 494.xx,
Study Design
496.xx, 770.2), pulmonary hypertension (416.xx),
In this retrospective study, a US commercial insur-
pulmonary embolism (415.xx), or other pulmonary
ance database (Ingenix LabRx, Ingenix, Eden Prairie,
circulatory disorder (417.xx); or a filled prescription
October 2008 Clinical Therapeutics
lated from the gram weight of albuterol dispensed divided by 1/100 of the gram weight of the canister)
or >365 inhalation unit doses (solution or capsule,
calculated from the total volume of nebules or cap-
sules dispensed) of albuterol or levalbuterol within
365 days before the index date, indicating potential overreliance on a SABA1; ≥1 pharmacy claims for
oral corticosteroids (OCSs) within 365 days before
the index date; an urgent-care (UC) or emergency-
department (ED) visit for asthma (primary or second-
ary ICD-9-CM code 493.xx) followed by a prescrip-tion for an OCS (within 7 days of the visit) within 365 days before the index date; or a hospital admis-
sion for asthma within 365 days before the index
date. Previous claims for leukotriene modifiers or theophylline were not used to categorize patients for more severe disease; these drugs are not preferred
treatments, and there are no guidelines recommended
for patients whose disease is not well controlled with
these medications.1 Patients classified as no ICS use/milder disease had an index FPS prescription but did not meet any of the previously noted criteria.
For each filled prescription of an albuterol canister,
the Ingenix database reports the total metric quantity
dispensed (in grams of albuterol) and a National Drug Code (NDC) value for each prescription fill dispensed.
Figure 1. Flowchart of patient selection from a
Using the NDC value, the Multum drug database
(Denver, Colorado) was cross-referenced for the total
weight of albuterol contained in each package unit
that was dispensed. The ratio of grams dispensed per fill (from Ingenix) to grams per canister dispensed
who had ≥1 pharmacy claims for flutica-
(from Multum) was used to estimate number of can-isters dispensed per fill. However, because this was a
dose combination between October 1, 2004, and September 30, 2006.
retrospective study, the reliability of these values could not be evaluated. Analysis
for >1 dose strength of FPS on the index date. Only 1 dose
In addition to recording patients’ age and sex at the
strength was allowed, in order to analyze FPS use
index date and classifying them as either ICS use/more
based on dosage. This criterion excluded only 1.1% of
severe disease or no ICS use/milder disease, several
other variables of interest were identified: dose of FPS
Patients were classified into either of 2 study groups
at the index date; medical and prescription history for
based on their claims experience in the preindex pe-
the 365 days before the index date, including use of
riod: ICS use/more severe disease or no ICS use/milder
SABAs, LABAs, ICSs, and OCSs; and asthma-related
disease. Those classified as ICS use/more severe dis-ease were required to satisfy at least 1 of the following
Continuous variables were characterized by mean
criteria: at least 1 pharmacy claim for an ICS with-
and standard deviation, and categorical variables
in 365 days before the index date; >365 doses of al-
were characterized by frequency and percentage
buterol from an inhaler (2 inhalations per dose, calcu-
within each category. All analyses were performed
Volume 30 Number 10 H. Friedman et al.
using SAS version 8.2 software (SAS Institute Inc., Cary, North Carolina).
Table I. Demographic characteristics and flutica-
Study Population
The population of eligible patients (N = 87,459)
had a mean age of 37.3 years, and 60.8% were female
(Table I). Patients were from many regions of the
United States: 24% from the Southeast, 23% from the
Great Lakes region, 23% from the South Central re-
gion, 13% from the Northeast, 11% from the Moun-
tain states, 5% from the Western states, and <1%
from unknown regions of the United States. On the index date, 93.8% of the FPS prescriptions were for
the 100/50-μg (43.5%) or 250/50-μg (50.3%) doses. Outcomes
Patients’ preindex disease severity indicators are
summarized in Table II. Figure 2 shows the distribu-
tion of patients according to preindex ICS use or se-
verity classification. Of the total eligible population,
69.1% of patients were classified as no ICS use/milder disease (ie, had no evidence during the preindex period
of ICS use or disease severity warranting the use of 2 controller medications). Only 6.3% of patients in the total population had a claim for an ICS during the preindex period. Furthermore, during the preindex
In the subpopulation of patients with evidence of
period, 7.4% of patients had evidence of overreliance
previous ICS use or more severe disease in the pre-
on SABA treatment, and 22.7% were prescribed an
index period, 20.4% were prescribed an ICS, 73.5%
OCS. Rates of unscheduled asthma-related hospitaliza-
were prescribed an OCS, and 23.9% were estimated
tions, and ED or UC visits (plus an OCS prescription
to be overreliant on SABA use. In addition, 8.5% had
within 7 days), were very low: 1.5% and 1.1%, respec-
asthma-related hospitalizations, ED visits, or UC vis-
tively. As shown in Figure 3, patients using FPS at the
its. Each estimate was calculated from patient counts
higher doses during the preindex period were more
shown in Table II by dividing the number of patients
likely to have ICS use/more severe disease than those
with each criteria by the total number of ICS use/more
using a lower dose, although fewer than half of all pa-
severe disease patients (27,006); however, proportions
tients using even the highest strength of FPS had
do not total 100% because the groups are not mutu-
ally exclusive (eg, a patient could have received
The assessment of preindex prescription histories
both an OCS and an ICS prescription in the preindex
in the total population revealed that 48.8% of eligible
patients had no evidence of previous asthma medi-
As shown in Figure 4, ICS prescribing was reason-
cations during the 365 days. Furthermore, 17.5% of
ably constant throughout most of the study period.
eligible patients had received a SABA as the only
However, Figure 4 appears to show trends toward a
asthma medication before the initiation of FPS
small decrease in the proportion of patients with pre-
(Table III). For the Medicaid subpopulation with
index ICS prescriptions after the FDA issued its advi-
FPS claims in our study, only 9.9% had pre-
sory about LABAs in November 2005 and a small
index ICS claims, and 10.5% had preindex asthma-
increase in preindex ICS prescriptions after the FDA
related hospitalizations or ED/UC claims coded for
issued its mandate for boxed warnings for LABAs in
October 2008 Clinical Therapeutics
Table II. Assessment of preindex disease severity indicators in the total population examined from a retro-
spective analysis of a commercial insurance database. Data were analyzed for patients aged 12 to 62 years who had ≥1 pharmacy claims for fluticasone propionate/salmeterol (FPS) fixed-dose com-bination between October 1, 2004, and September 30, 2006.
UC/ED visits with OCS within 7 days of index date
ICS = inhaled corticosteroid; Rx = prescription; OCS = oral corticosteroid; SABA = short-acting β -agonist; UC/ED = urgent
care or emergency department. * Patients may have had >1 indicator of more severe disease. † Defined as ≥365 doses (according to the preindex period) of albuterol inhaler (2 inhalations per dose), or ≥365 inhalation
unit doses of albuterol or levalbuterol within 365 days preindex.
DISCUSSION
warning campaigns were instituted for a number of
Within a large population of asthma patients enrolled
drugs. The authors concluded that although prescrip-
in managed care plans, 93.7% were newly prescribed
tions for these drugs were sometimes reduced, such
an FPS regimen without filling a single-entity ICS pre-
campaigns were not always effective. For example, a
scription within the previous 365 days. Furthermore,
time-series analysis of prescriptions for propoxyphene
69.1% of all patients who were prescribed FPS in this
was conducted in the mid-1970s after both the FDA
study population did not have asthma resource utili-
and drug manufacturer initiated a campaign to inform
zation indicating sufficient disease severity to warrant
physicians of the high risk of habituation and overdose.
The refill rates of propoxyphene remained near a constant
For the patients prescribed FPS in the Medicaid
43% in the 8 quarters before and the 3 quarters after an
subpopulation, only a small percentage (9.9%) had a
FDA warning on no-refills.9 A recent retrospective
previous ICS claim. These findings for the Medicaid
study found that a greater proportion of Medicaid
subpopulation are consistent with those of a study
patients (48%) than commercially insured patients
that examined Medicaid and SCHIP claims in Arkan-
(11%) had preindex ICS use and discontinued using
sas,7 in which only 11% of new FPS users had a previ-
LABAs after the FDA advisory (28% and 17%, re-
ous ICS claim and <25% had claims for physician
spectively).10 These results are in contrast to those of
services or medications at levels suggestive of moder-
the present study, which found a relatively flat trend
for ICS prescriptions before and after the FDA advi-
One area of interest in the current study was the
sory and boxed warnings for LABAs. Differences be-
temporal relationship between FDA announcements
tween the present study results and those of the previ-
regarding FPS use and prescribing trends for this agent.
ous study might stem from differences in the study
Soumerai et al8 reviewed studies that evaluated the
designs. For instance, the previous study required pa-
prescribing patterns of physicians after government
tients to have prescriptions for a LABA (including
Volume 30 Number 10 H. Friedman et al.
One limitation of the present study was a lack of
information on direct clinical measures of asthma se-
verity. However, the proxy definition of mild asthma in our study was based on prescriptions for SABAs (ie,
<365 unit doses) and OCSs (ie, none) in the 365-day
preindex period, and on the frequency of exacerba-tions, ED visits, or hospitalizations (ie, none) in the preindex period. Similar proxy measures of asthma severity were used in an observational study based on claims analyses.11 The proxy measures of asthma se-
verity used in the present study appear to be consis-tent with asthma management guidelines that dis- tinguish between levels of asthma severity (mild,
moderate, and severe) in previously untreated patients and levels of asthma control (well controlled, partly controlled, uncontrolled) that patients achieve with their current therapy.12 Patients in the present study who were overreliant on SABAs or had asthma-related ED visits or hospitalizations were, at best, partly con-
trolled based on guideline definitions and were classi-
use or severity classification in the total
fied as having more severe asthma that may have
warranted treatment with FPS as initial controller
therapy. In contrast, patients defined as having mild
asthma in the present study had low numbers of pre-
aged 12 to 62 years who had ≥1 pharma-
index SABA claims and no preindex ED visits or hos-
pitalizations, and the vast majority had no preindex
ICS prescription. Based on the guidelines, these pa-
tients should have received prescriptions for an ICS
before FPS therapy was initiated unless they presented
Methods section for the definition of more severe disease.)
to their physicians with signs or symptoms of poor asthma control.
Different criteria for classification of asthma severity
have been used elsewhere. In The Epidemiology and
FPS) in the preindex period and for an anti-
Natural History of Asthma: Outcomes and Treatment
asthmatic drug in the postindex period. This require-
Regimens (TENOR) study,13 3% of patients were clas-
ment would select patients with more severe asthma
sified by their physicians as having mild persis-
than those in the present study, which required only
tent asthma that they considered difficult to treat. The
TENOR study found that 6% of mild asthma patients
Although the cost of a drug (ie, copayments or
had ED visits within the previous 3 months.This fig-
cost-sharing provisions) may have affected physician
ure is >5 times higher than the proportion of patients
and patient behavioral choices, such as which drug to
in the present study (1.1%) with preindex ED visits.
prescribe or how often to use the medication, the da-
An evaluation of asthma severity classification of
tabase does not include this information and the cur-
TENOR patients based on criteria of the 2002 NAEPP
rent study does not address these issues. It is also not
guidelines found that 29% of patients had mild per-
known how accurately pharmacy claims data reflect
sistent asthma, whereas only 4% of TENOR patients
patients’ adherence to prescribed treatment. In addition,
had mild persistent asthma based on the criteria of the
the prescribing information of physicians by specialty
Global Initiative for Asthma guidelines.14
was not captured in the database and is beyond the scope
Findings in the present study do not preclude the
of this study. Further research on this topic is needed.
possibility that some patients may have had no prein-
October 2008 Clinical Therapeutics
No ICS use/milder diseaseICS use/more severe disease
Figure 3. Index fluticasone propionate/salmeterol (FPS) fixed-dose combination doses in the total study
population from a retrospective analysis of a commercial insurance database. Data were analyzed for patients aged 12 to 62 years who had ≥1 pharmacy claims for FPS between October 1, 2004, and September 30, 2006. (See the Materials and Methods section for the definition of more severe dis-ease.) ICS = inhaled corticosteroid.
Table III. One-year preindex prescription history in the total population examined in a retrospective analysis
of a commercial insurance database. Data were analyzed for patients aged 12 to 62 years who had ≥1 pharmacy claims for fluticasone propionate/salmeterol (FPS) fixed-dose combination between October 1, 2004, and September 30, 2006.
SABA = short-acting β -agonist; LABA = long-acting β -agonist; ICS = inhaled corticosteroid; OCS = oral corticosteroid.
Volume 30 Number 10 H. Friedman et al.
Figure 4. Inhaled corticosteroid prescription trends relative to US Food and Drug Administration (FDA) ad-
visory and long-acting β -agonist (LABA) boxed warnings from a retrospective analysis of a com-
mercial insurance database. Data were analyzed for patients aged 12 to 62 years who had ≥1 phar-macy claims for fluticasone propionate/salmeterol fixed-dose combination between October 1, 2004, and September 30, 2006. Point A represents FDA advisory on LABA safety; point B represents FDA-mandated boxed warnings for LABAs.
dex ICS claims or asthma history but presented on the
step-up therapy is not often applied as recommended
index date with asthma of a severity that warranted
in asthma management guidelines or evaluated in con-
initial treatment with 2 controller medications. Some
trolled clinical trials. For example, a review of medical
patients may have had poor asthma control because
records in Olmsted County, Minnesota, found that
of treatment failure, whereas others may have had
prescriptions for asthma medications were episodic,
poor asthma control because of nonadherence to the
with 52% of medication changes occurring during
prescribed treatment. Medication nonadherence is a
office visits after an asthma flare-up, and 14% occur-
major obstacle to asthma control, and it can be a
ring in the ED. In addition, 64% of the medication
problem with ICS therapy, specifically. Previous stud-
changes were step-ups, whereas 9% were step-downs
ies have shown that, in practice, the underuse of ICSs
in current medication dosage and 4% were step-
and overuse of β -agonists, whether short- or long-
downs in the class of prescribed medication.21 The use
acting, are common.15,16 In spite of this, the clinical
of FPS for patients who have not stepped up through
benefits of stepping up from low-dose single-entity
single-entity ICS may not be necessary unless the pa-
ICS to combined ICS/LABA therapy in patients not
tients’ asthma severity clearly warrants initiation of
adequately controlled with single-entity ICS are well
treatment with 2 controller therapies.22–24
established and reflected in the NAEPP guidelines.1
Many patients with asthma are prescribed ICS/
Clinical studies have shown that the addition of a
LABA combination therapy before it is necessary,
LABA to an ICS in patients whose asthma is not ade-
when viewed in the context of NAEPP guidelines and
quately controlled with ICS monotherapy improves
the FDA boxed warning on LABA-containing combi-
asthma control by a greater extent than is achieved
nation products. Although the reasons for potential
by increasing the ICS dose17–19 or adding an antileu-
overuse of ICS/LABA combination therapy have not
kotriene.20 In real-world clinical practice, however,
yet been elucidated, the practice of reserving the use of
October 2008 Clinical Therapeutics
4. US Food and Drug Administration. Advair Diskus, Advair
these combination agents for patients whose disease
HFA, Brovana, Foradil, Perforomist, Serevent Diskus, and
is not adequately controlled with single-entity ICS
Symbicort information (long acting beta agonists). http://
per asthma management guidelines is not followed
www.fda.gov/cder/drug/infopage/LABA/default.htm.
5. Advair Diskus (fluticasone propionate and salmeterol
CONCLUSION
inhalation powder) [prescribing information]. Research
More than two thirds of the patients who initiated
Triangle Park, NC: GlaxoSmithKline; 2008.
FPS treatment had neither received an ICS prescrip-
6. Nathan RA. Utilizing mometasone furoate dry powder
tion before the first FPS pharmacy claim nor had evi-
inhaler to get back to basics with asthma guidelines.
dence of asthma severity that would appear to war-
Presented at: Aspen Allergy Conference; July 26–29, 2006;
rant the use of an ICS/LABA combination.
7. Helm ME, Vargas PA, Jones SM. Advair prescribing pat-
ACKNOWLEDGMENTS
terns in a state Medicaid and child health insurance
program. J Allergy Clin Immunol. 2007;119(Suppl):S170.
This study was sponsored by Schering-Plough Corpo-
8. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug
ration. Editorial assistance was provided by Ken Kauff-
prescribing in primary care: A critical analysis of the
man, BSc, and Erin P. Scott, PhD; this assistance was
experimental literature. Milbank Q. 1989;67:268–317.
funded by Schering-Plough. Drs. Friedman and Rear-
9. Soumerai SB, Avorn J, Gortmaker S, Hawley S. Effect of
don provide consulting services to Schering-Plough.
government and commercial warnings on reducing pre-
Ms. Crespi is an employee of Schering-Plough. Dr. Wil-
scription misuse: The case of propoxyphene. Am J Public
cox has received grant/research support from Adams
Respiratory Therapeutics, Altana AG (Nycomed), Astra-
10. Baker D, Rasu R, Burke S, Toe D. Evaluation of asthma-
Zeneca, Boehringer Ingelheim, Forest Laboratories,
related utilization in a managed care population following
Inc., GlaxoSmithKline, Merck & Company, Novartis,
a FDA public health advisory on long-acting β2-agonists.
Ortho-McNeil, Pfizer Inc., Sepracor Inc., and Schering-
Presented at: Academy of Managed Care Pharmacy 19th
Plough, and is a stock shareholder of GlaxoSmithKline.
Annual Meeting; April 13, 2007; San Diego, Calif.
11. Colice G, Wu EQ, Birnbaum H, et al. Healthcare and
Dr. Yawn has received research grants from Astra-
workloss costs associated with patients with persistent
Zeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer,
asthma in a privately insured population. J Occup Environ
and Schering-Plough for work in asthma and chronic
obstructive pulmonary disease; she has served as an
12. Global Initiative for Asthma (GINA). GINA report: Global
advisor to Schering-Plough, AstraZeneca, Merck &
strategy for asthma management and prevention. http://
Company, Boehringer Ingelheim, and Pfizer.
www.ginasthma.com/Guidelineitem.asp??l1=2&l2= 1&intId=60. Accessed December 6, 2006. REFERENCES
13. Dolan CM, Fraher KE, Bleecker ER, et al, for the TENOR
1. National Heart, Lung, and Blood Institute. Expert Panel
Study Group. Design and baseline characteristics of the
Report 3 (EPR3): Guidelines for the diagnosis and man-
epidemiology and natural history of asthma: Outcomes
agement of asthma. http://www.nhlbi.nih.gov/guidelines/
and Treatment Regimens (TENOR) study: A large cohort
asthma/index.htm. Accessed April 16, 2008.
of patients with severe or difficult-to-treat asthma.
2. US Food and Drug Administration. FDA Public Health
Ann Allergy Asthma Immunol. 2004;92:32–39.
Advisory: Serevent Diskus (salmeterol xinafoate inhala-
14. Miller MK, Johnson C, Miller DP, et al, for the
tion powder), Advair Diskus (fluticasone propionate and
TENOR Study Group. Severity assessment in asthma:
salmeterol inhalation powder), Foradil Aerolizer (formot-
An evolving concept. J Allergy Clin Immunol. 2005;116:
erol fumarate inhalation powder). http://www.fda.gov/
cder/drug/advisory/LABA.htm. Accessed December 4,
15. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical
management of asthma in 1999: The Asthma Insights and
3. Nelson HS, Weiss ST, Bleecker ER, et al, for the SMART
Reality in Europe (AIRE) study. Eur Respir J. 2000;16:802–
Study Group. The Salmeterol Multicenter Asthma Re-
search Trial: A comparison of usual pharmacotherapy for
16. Adams RJ, Fuhlbrigge A, Guilbert T, et al. Inadequate use
asthma or usual pharmacotherapy plus salmeterol [pub-
of asthma medication in the United States: Results of the
lished correction appears in Chest. 2006;129:1393]. Chest.
asthma in America national population survey. J Allergy Clin Immunol. 2002;110:58–64. Volume 30 Number 10 H. Friedman et al.
DS, et al, for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma [published correction appears in N Engl J Med. 1998;338:139]. N Engl J Med. 1997;337:1405–1411.
quet J, et al, for the GOAL Investiga-tors Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med. 2004;170:836–844.
berg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol. 2001;107:783–789.
20. Ringdal N, Eliraz A, Pruzinec R, et al,
for the International Study Group. The salmeterol/fluticasone combi-nation is more effective than flutica- sone plus oral montelukast in asth-ma. Respir Med. 2003;97:234–241.
et al. Asthma treatment in a pop- ulation-based cohort: Putting step-up and step-down treatment chang- es in context. Mayo Clin Proc. 2007;82:414–421.
ment of asthma. Am Fam Physician. 2006;74:232.
right time. Chest. 2006;130(Suppl 1): 29S–40S.
Services. Judicious use of Advair. http://www.dhs.state.mn.us/main/groups/business_partners/documents/ pub/dhs_id_053529.pdf. Accessed December 4, 2006. Address correspondence to: Howard Friedman, PhD, Analytic Solutions, Inc., 26 Prince Street, Suite 2B, New York, NY 10012. E-mail: howard@ analytic-consulting.com October 2008
Eytan Fox, Israel's Premier Gay Director Takes a Surprising Tu. http://www.hartfordadvocate.com/entertainment/movies/ht-eyta. www.hartfordadvocate.com/entertainment/movies/ht-eytan-fox-israels-premier-gay-director-takes-a-surprising-turn-with-mary-lou-20110520,0,1945618.story hartfordadvocate.com Eytan Fox, Israel's Premier Gay Director Takes a Surprising Turn with 'Mary Lou' For Eytan Fox
GSO Capital Partners International LLP Carador Plc (the “Fund” or “the Company”) September 20081 Fund Performance2: Monthly LTM Total Price/Net Dividend Inception 5 Carador Price +0.00% 23.55% -11.89% -13.72% -10.12% +7.75% Carador NAV General Commentary Fund performance NAV decreased to [64.98]c in September due to the quarterl